|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The survival analysis showed that high AR mRNA is associated with poor survival of stomach adenocarcinoma and low-grade glioma, but better survival of adrenocortical carcinoma, kidney renal clear cell carcinoma, acute myeloid leukemia, liver hepatocellular carcinoma, ovarian serous cystadenocarcinoma, and skin cutaneous melanoma based on AR mRNA, protein or AR-score.
|
31759122 |
2020 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accordingly, the investigation of lncRNAs is improving our understanding of genitourinary cancers, from development to progression and dissemination. lncRNAs are involved in major oncogenic events in genitourinary malignancies, including androgen receptor (AR) signalling in prostate cancer, hypoxia-inducible factor (HIF) pathway activation in renal cell carcinoma and invasiveness in bladder cancer, as well as multiple other proliferation and survival mechanisms.
|
31110275 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of RIP assay and AGO2 assay revealed that AR could bind ASS1P3 to increase RCC cell proliferation via altering miR-34a-5p function, which could bind to the 3'UTR of ASS1 to suppress its protein expression.
|
31000693 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, higher androgen receptor expression was correlated with male patients, low tumor grade and early stage of renal cell carcinoma.
|
30919276 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, our results suggest the potential role of AR as a target for therapeutic interventions, in combination with RTKi, to overcome drug resistance in RCC.<b>Significance:</b> These findings highlight the therapeutic potential of targeting the androgen receptor to overcome RCC resistance to receptor tyrosine kinase inhibitors.<i></i>.
|
29572225 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting this newly identified AR-circHIAT1-mediated miR-195-5p/29a-3p/29c-3p/CDC42 signals may help us develop potential new therapies to better suppress ccRCC metastasis.
|
28089832 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results provide a unique mechanism by which AR can either increase or decrease ccRCC metastasis at different sites and may help us to develop combined therapies using anti-AR and anti-VEGF-C compounds to better suppress ccRCC progression.The incidence of renal cell carcinoma is higher in males than in females due to the different androgen receptor signaling but the molecular mechanisms behind this gender bias are unclear.
|
29030639 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We first observed in vivo that castration retards the growth of AR-positive RCC tumour xenograft in mice.
|
28253524 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals.
|
28644440 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of AR was measured by immunohistochemistry and assessed by digital image analysis using a tissue microarray containing tumor tissue of a large and well-documented series of RCC patients with long-term follow-up information.
|
29108248 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting this newly identified C1QBP/YBX1/AR/MMP9 signal pathway may provide a new potential therapy to better suppress RCC metastasis.
|
28107702 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ingenuity pathway analysis also identified overlapping pathways and upstream regulators enriched in AR-associated genes in ccRCC and pRCC.
|
26814892 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The negative feedback modulation between LncRNA-SARCC/AR complex and HIF-2α signaling may then lead to differentially modulated RCC progression in a VHL-dependent manner.
|
26973243 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting this newly identified AR-induced AKT → NF-κB → CXCL5 pathway may facilitate the development of new therapies for slowing RCC progression.
|
27848972 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Androgen receptor mRNA expression was evaluated by quantitative real-time polymerase chain reaction in 115 tumor samples from patients with primary pathological stage T1 or T2 (pT1/pT2) renal cell carcinoma and 57 specimens of corresponding normal kidney tissue.
|
25796113 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blockade of the newly identified signal by AR inhibition or miRNA-145 mimics has promising therapeutic benefit to suppress RCC progression.
|
26304926 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that estrogen receptor β (ERβ) was more highly expressed in RCC cell lines (A498, RCC-1, 786-O, ACHN, and Caki-1) than in breast cancer cell lines (MCF-7 and HBL-100); however, no androgen receptor (AR) or estrogen receptor α (ERα) could be detected by western blot.
|
23460808 |
2013 |